PRESS RELEASE

Mithra’s European Advisory Board for Estelle will meet during the ESC congress (European Society of Contraception) in Basel on May 4th 2016

- Mithra has set up a scientific committee composed of international experts to support the last development steps of Estelle®, its contraceptive product candidate based on Estetrol.

- The European or American scientific committees, set up by Mithra and its own scientific committee, are aimed at gathering impressions and recommendations from the international experts in the contraception field. These committees will be moderated by Mitchell Creinin, global expert in contraception of the Davis University in Sacramento, California.

- During the ESC (European Society of contraception) held in Basel from May 5th to 7th, 2016, Mithra will gather its experts and practitioners board and will present the last results of the project Estelle to the scientific community during a symposium entitled "Estelle, new contraceptive pill with fetal estrogen, Estetrol".

Liège, Belgium, 3 May 2016 – In order to support the last development steps and to prepare its candidate product for a future introduction on the market, Mithra set up an international and European advisory committee. Composed of 7 international European experts in gynecology, this committee will advise Mithra on its development, but also on the clinical relevance and the added value of Estetrol in the contraception field. These Key Opinion Leaders will work with Mithra in order to confront development plans with market needs. The next committee meeting is planned on May 4th in Basel, Switzerland, during the ESC Congress (European Society of contraception and Reproductive Health) and will be moderated by Mitchell Creinin, a world expert in contraception.

The following members compose the first international and European scientific committee for the development of Estelle®:

- Prof. Mitchell Creinin, Professor, Director of Family Planning Department of Obstetrics and Gynecology University of California, Sacramento;
- Prof. Kristina Gemzell Danielsson, Professor and Chair of Obstetrics and Gynecology at the Department of Women’s and Children’s Health, Karolinska Institutet, and Karolinska University Hospital, Stockholm, Sweden;
- Prof. Ali Kubba, Lead Consultant Gynecologist in the Colposcopy Unit and the Community Reproductive Healthcare Unit - Guy’s and St Thomas’ NHS Foundation Trust;
- Prof Johannes Bitzer, Former Chairman and Professor of the Department of Obstetrics and Gynecology at the Basel University Hospital;
- Prof. Tommaso Simoncini, Professor of Obstetrics and Gynecology Department of Clinical and Experimental Medicine, University of Pisa;
- **Prof. Lee Shulman**, Anna Ross Lapham Professor in Obstetrics and Gynecology and Chief of the Division of Clinical Genetics at the Feinberg School of Medicine at Northwestern University in Chicago, Illinois;
- **Dr. Diana Mansour**, Consultant in Community Gynecology and Reproductive Health Care and Head of Sexual Health Services at New Croft Centre, Newcastle.

This committee will be chaired by Prof. Herjan Coelingh Bennink and Prof. Jean-Michel Foidart, members of Mithra’s scientific committee.

François Fornieri, CEO of Mithra Pharmaceuticals: “*We are extremely proud that we’ve been able to gather so many Key Opinion Leaders around this project, which is a key objective for Mithra. The interest these international experts showed demonstrates how strong the scientific community wish to get involved in the future of contraception through such innovative and promising projects like Estelle.*”

A second international scientific committee will be organized in Washington DC in June. It will gather a panel of American and Canadian experts to pursue this world market analysis and support development plans in the USA and Canada.

**Pictures**

For pictures of François Fornieri, please click here on the following link:


**For more information, please contact:**

**Press**

Julie Dessart  
Chief Communication Officer  
+32 4 349 28 22  
+32 475 86 41 75  
press@mithra.com

**Investor Relations**

François Fornieri, CEO  
+32 4 349 28 22  
investorrelations@mithra.com

**About Mithra**

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. dr. Jean-Michel Foidart, is a pharmaceutical company focused on Women’s Health. Mithra’s mission is to support and assist women at every stage of their life, thereby improving their overall quality of life. As such the Company aims to become a worldwide leader in women’s health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and complex therapeutical entities in four therapeutic fields of women’s health, fertility and contraception, menopause and osteoporosis, vaginal infections and cancers.
Mithra has a total headcount of approximately 85 staff members and is headquartered in Liège, Belgium. Further information can be found at: www.mithra.com

**Important information**

The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words “believes”, "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company’s actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.

To subscribe to Mithra’s newsletter, visit investors.mithra.com